CYP2D6*3 (A2549del), *4 (G1846A), *10 (C100T) and *17 (C1023T) genetic polymorphisms in Iranian breast cancer patients treated with adjuvant tamoxifen

There is controversy regarding the efficacy of tamoxifen in breast cancer patients who are carriers of cytochrome P450 2D6 (CYP2D6) gene polymorphisms. Poor metabolizer genotypes may not fully convert tamoxifen to its active metabolite endoxifen and thus have less exposure to anti-estrogen therapy....

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Biomed Rep
Prif Awduron: Saghafi, Fatemeh, Salehifar, Ebrahim, Janbabai, Ghasem, Zaboli, Ehsan, Hedayatizadeh-Omran, Akbar, Amjadi, Omolbanin, Moradi, Siavash
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: D.A. Spandidos 2018
Pynciau:
Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6176100/
https://ncbi.nlm.nih.gov/pubmed/30345040
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/br.2018.1145
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg